Recently, the academic article "The Impact of Sucralose and Neotame on the Safety of Metal Precipitation in Electronic Cigarettes," independently researched and written by iMiracle's Innovation Lab, was accepted by the internationally recognized journal Frontiers in Physiology. This SCI paper marks another significant advancement in the company's scientific research on electronic vaping.
Sweeteners are crucial components in e-liquid formulations, used to enhance flavor. This paper focuses on two commonly used sweeteners—sucralose and neotame—and investigates their impact on the release of heavy metals (such as nickel, chromium, and iron) during the vaping process.
The research simulated an e-liquid environment using base liquids containing two different concentrations of these sweeteners, testing the heavy metal content in the liquid and aerosol produced after heating. The results indicated that the metal content in the vapor changed correspondingly with different levels of sucralose in the e-liquid.
Additionally, cytotoxicity tests were conducted, revealing that e-liquids with higher concentrations of sucralose had a more significant impact on cell viability. The study suggests that the use of sucralose in e-liquids should be minimized or replaced with the relatively safer neotame.
The SCI journal Frontiers in Physiology, which accepted this paper, is an internationally recognized medical journal. According to its official website, the journal has been cited over 300,000 times globally. This research provides theoretical foundation and scientific guidance for the use of sweeteners in electronic vaping products.
Product safety has always been a top priority in iMiracle's product development. The company is committed to strictly controlling the safety of e-liquid additives and is also increasing its efforts in developing innovative sweeteners, relying on new technologies to safely recreate various flavors.
For a long time, iMiracle has been exploring safer electronic vaping products while ensuring compliance, contributing to the industry's innovative advancement. The iMiracle Innovation Lab was established in 2022 with an initial investment of over 40 million RMB and covers an area of approximately 3,000 square meters. The lab is equipped with over 200 advanced scientific research instruments. With a research and development team of more than 100 people, the company's robust R&D capabilities and investment in equipment ensure the quality and safety of its products.
Currently, the Innovation Lab can provide over 350 tests, including those for e-liquid, electronic vapor emissions, product reliability, materials, toxicology, FDA Harmful and Potentially Harmful Constituents (HPHCs), EU Restriction of Hazardous Substances (RoHS), and EU REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) regulations.
The company places great emphasis on product quality and safety. With industry-leading technology and rigorous standards, iMiracle has successfully obtained GMP certification, ISO9001, ISO14001 quality system certifications, and its products have passed CE safety certifications, establishing itself as a global leader in the electronic vaping industry.
Additionally, iMiracle holds nearly 400 authorized patents worldwide, forming a safe and efficient R&D system and product innovation mechanism. The iMiracle R&D Lab will continue to enhance its innovation and research capabilities in electronic vaping, consistently launching industry-leading products and driving innovation, iteration, and advancement within the industry.
